On Wednesday, in the course of current trade, Shares of The Western Union Company (NYSE:WU), gained 3.48%, and is now trading at $21.69, hitting its highest level.
Today, The Western Union Foundation declared it has surpassed a major milestone, donating more than US$100 million in support to more than 2,700 non-governmental organizations (NGOs) to provide support to thousands of families and individuals in more than 135 countries and territories.
The Western Union Foundation works with a full spectrum of large global NGOs to small local non-profits and charities worldwide counting UNICEF, Save the Children, Mercy Corps, Pratham and others.
From increasing global access to school and improving the quality of education to providing relief and rebuilding efforts for families and communities influenced by disasters worldwide, the Western Union Foundation has supported charitable organizations dedicated to providing a better future for individuals, families and communities throughout the world.
In 2013 and 2014, more than 72 percent of all Western Union employees, or 7,580 employees across 53 countries, made a donation to the Western Union Foundation. In addition, the Foundation has partnered with hundreds of Western Union Agents and vendor partners to create a true collaborative partnership instrumental in reaching this milestone.
The Western Union Company provides money movement and payment services worldwide. The company operates in three segments: Consumer-to-Consumer, Consumer-to-Business, and Business Solutions. The Consumer-to-Consumer segment offers cash money transfer services involving walk-in agent locations.
During an Afternoon trade, Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), gained 9.66%, and is now trading at $14.53.
On May 1, Sarepta Therapeutics, declared equity awards granted on April 30, 2015, that were formerly approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to three individuals hired by Sarepta in April 2015.
The employees received, in the aggregate, options to purchase 20,375 shares of Sarepta’s common stock. The options have an exercise price of $12.20 per share, which is equal to the closing price of Sarepta’s common stock on April 30, 2015. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Finally, Skullcandy, Inc. (NASDAQ:SKUL), lost -26.17% Wednesday.
Skullcandy, declared financial results for the first quarter ended March 31, 2015.
First quarter 2015 results as compared to same quarter in preceding year
- Net sales: $46.2 million vs. $39.1 million (+18%, or +21% currency neutral basis*)
- Gross margin: 40.5% vs. 46.5% (-600 basis points)
- Selling, general and administrative expense (SG&A): $22.4 million vs. $22.1 million (+1%)
- SG&A expense as a percent of net revenue: 48.4% vs. 56.5%
- Operating loss: $3.6 million vs. $3.9 million, (7% improvement)
- Net loss per share: $(0.13) vs. $(0.12).
Gross profit in the first quarter of 2015 raised 3% to $18.7 million from $18.2 million in the same quarter of the preceding year. Gross margin reduced to 40.5% in the first quarter of 2015 from 46.5% in the same quarter in 2014 primarily due to foreign currency depreciation, raised air-freight and warehousing expense to overcome west-coast port slowdowns, and product mix shift to gaming products.
Skullcandy Inc. designs, markets, and distributes audio and gaming headphones, earbuds, speakers, and other accessories under the Skullcandy, Astro Gaming, and 2XL brands in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
